LGM2605 Nrf2 Pathway Modulation for Steroid-Resistant Asthma

Solution Overview

Problem

Current treatments for asthma, ozone-induced damage, radiation exposure, and lung cancer lack effective, non-toxic, and affordable options, particularly for steroid-resistant asthma and ozone-induced inflammation, and existing chemopreventive agents are either toxic or ineffective in reducing oxidative stress and airway hyperreactivity.

Innovation Solution

Chemically synthesized secoisolaricirecinol diglucoside (SDG) and its analogs are administered to treat asthma, prevent ozone-induced damage, and protect against radiation and carcinogen exposure, acting through anti-oxidative pathways and immune system modulation independent of glucocorticoid receptors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If glucocorticoids are used to treat severe asthma and airway inflammation, then anti-inflammatory effects are achieved, but they are ineffective in steroid-resistant patients and have toxicity concerns

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the mechanism of action parameter from glucocorticoid receptor-dependent to Nrf2 pathway-dependent. LGM2605 acts through oxidative stress reduction and Nrf2 activation, representing a fundamental parameter change in the therapeutic approach, thereby overcoming steroid resistance while maintaining anti-inflammatory effectiveness

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent substitutes the glucocorticoid receptor mechanism with an alternative biochemical pathway involving Nrf2 activation and oxidative stress reduction. This mechanism substitution provides efficacy in patients who resist traditional glucocorticoid therapy

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If conventional chemopreventive agents are used to reduce oxidative stress and airway hyperreactivity, then some protective effects are achieved, but they are either toxic or ineffective

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical structure parameter from conventional chemopreventive agents to secoisolariciresinol diglucoside (SDG) and its analogs. This structural parameter change confers both effectiveness in reducing oxidative stress and airway hyperreactivity, and non-toxicity, simultaneously resolving the contradiction

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent converts the harmful effect of oxidative stress into a beneficial therapeutic target. By activating the Nrf2 pathway and enhancing endogenous antioxidant defenses, the compound transforms the body's response to oxidative stress from harmful to protective, achieving chemoprevention without toxicity

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If ozone exposure is used to study pulmonary inflammation and airway hyperreactivity, then a relevant asthma model is created, but it causes significant lung damage and inflammation

Engineering Contradiction:
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies LGM2605 treatment before or during ozone exposure to prevent lung damage while allowing the ozone-induced inflammation model to proceed. This preliminary protective action preserves research model validity by maintaining the inflammatory response necessary for studying asthma mechanisms, while preventing excessive lung damage

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent introduces LGM2605 as an intermediary substance that mediates between ozone exposure and lung tissue. This intermediary protects lung cells from ozone-induced damage through Nrf2 activation and antioxidant mechanisms, while allowing the inflammatory model to remain valid for research purposes

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

SDG effectively reduces airway inflammation, oxidative stress, and hyperreactivity, providing radioprotection and chemoprevention without toxicity, making it a promising treatment for asthma and lung cancer prevention.

Implementation Method 1

LGM2605 is a non-toxic, synthetic lignan secoisolariciresinol diglucoside shown to have robust anti-inflammatory effects independent of the glucocorticoid receptor. Indeed, this novel compound is thought to act via anti-oxidative induction of nuclear factor-E2 related factor 2 (Nrf2) expression, free radical scavenging

Methodology Applied
Scientific EffectFree radical scavenging: Oxidation

Implementation Method 2

this novel compound is thought to act via anti-oxidative induction of nuclear factor-E2 related factor 2 (Nrf2) expression, free radical scavenging, inhibition of myeloperoxidase activity, and impaired NLRP3 inflammasome and NF-κB activation. Expression of Nrf2 in the lung reduced oxidative stress and maintains the proper Th1/Th2 balance

Methodology Applied
Scientific EffectAnti-oxidative induction of Nrf2 expression: Oxidation

Data Source

PatentUS12029745B2Effects of LGM2605 on a primate model of asthma
Publication Date: 2024.07.09
  • US12029745B2 patent drawing
  • US12029745B2 patent drawing
  • US12029745B2 patent drawing

AI summary

The invention provides compositions and methods for treating asthma in a subject in need thereof comprising administering chemically synthesized secoisolaricirecinol diglucoside (SDG), and in particular, a racemic mixture of the SDG (LGM2605), stereoisomers thereof, metabolites thereof, and analogs thereof. Also provided are methods for treating or preventing ozone-induced damage in a subject in need thereof.